AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 201 min read$CRL

Charles River (NYSE: CRL) CEO makes 528-share gift of common stock

Charles River Laboratories (CRL) CEO Birgit Girshick gifted 528 shares of common stock on 2026-08-19, leaving her with 35,485 direct and 43,803 indirect shares via a revocable trust. The gift was reported at $0.00 per share, with no Rule 10b5-1 trading plan involved.

Original reporting
stocktitan.net
Published Aug 20, 2026, 9:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$CRL
Neutral
low confidence
Mentioned
$CRL
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

Routine insider gift with no immediate price effect; serves compliance transparency.

02

Market read

The filing is a standard compliance disclosure with negligible trading relevance.

03

What to watch

Potential tax or estate planning motives behind the revocable trust structure.

Relevance 4/10Novelty 4/10Timing: gift disclosed on 2026-08-19

Background

Form 4 filings disclose insider transactions; gifts are reported at zero value.

Company-level read

Ticker impact

$CRLNeutralLow confidence
Context

CEO Birgit Girshick gifted 528 shares of common stock, disclosed in a Form 4 filing on 2026-08-19.

Expected impact

Minimal to none; unlikely to move the stock.

Evidence & confidence

Small share count relative to total holdings and no cash consideration; typical for personal estate planning.

Market effects

Sector

No material effect on the life‑science services sector.

Regional

Limited to U.S. investors; no broader regional impact.

Global

None

Counterpoint

What could challenge this read

Some investors may view any insider activity as a signal, but the gift size is too small to imply confidence or concern.

Key entities

  • person
    Birgit Girshick

    Chief Executive Officer of Charles River Laboratories

  • company
    Charles River Laboratories International, Inc.

    Provider of drug discovery and development services

Read at source← All news

Related articles

AUG 21
$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

yahoo.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
AUG 14
$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

yahoo.com6 min
AUG 9
$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

simplywall.st6 min
AUG 7
$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.

simplywall.st6 min